25 Oct, 2023 10:53 AM
SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Aust...read more
24 Oct, 2023 08:13 AM
Dear Fellow Shareholders,
It’s my pleasure to welcome all our shareholders to Immutep’s Annual General Meeting 2023, a year that has seen Immutep report very encouraging clinical data...read more
16 Oct, 2023 10:09 AM
New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST
Immute...read more
03 Oct, 2023 09:42 AM
SYDNEY, AUSTRALIA – 3 October 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing...read more
21 Sep, 2023 09:17 AM
SYDNEY, AUSTRALIA – September 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company develop...read more
08 Sep, 2023 11:36 AM
SYDNEY, AUSTRALIA – 8 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2023 Annual General M...read more
06 Sep, 2023 08:52 AM
SYDNEY, AUSTRALIA – 6 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical stage biotechnology company developing nov...read more